LuciAlpe (Alpelisib) 150mg 28 Tablets | Lucius Laos Generic | GLT

Generic Information: LuciAlpe (Alpelisib) — Lucius Laos Generic

LuciAlpe is the alpelisib product of Lucius Pharmaceuticals (Lao) Co., Ltd., a generic manufacturer based in Vientiane whose 25,000-square-meter plant turns out more than two hundred off-patent medicines for markets where originals are priced out of reach. The product is registered with the Lao FDA under registration number 03 L 1076/24 (test report 0386-24) — a real, checkable regulatory record, which is exactly what separates a documented Lao generic from anonymous internet pills. Each carton holds 28 film-coated tablets of 150 mg with a 24-month shelf life, and the blister matches the picture on this page: white and pink, Lucius branding, strength printed plainly.

What Is LuciAlpe (Alpelisib) Used For?

LuciAlpe carries the two internationally established uses of alpelisib: with fulvestrant, for HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after progression on endocrine therapy; and — as the Lao label follows the reference labeling — treatment of severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) in patients 2 years and older who need systemic therapy. In everyday practice the overwhelming majority of prescriptions are the breast cancer line, and the practical requirement is the same everywhere: a documented PIK3CA mutation from tumor tissue or blood before the first tablet, because without the mutation there is nothing for the drug to hit.

How Does LuciAlpe (Alpelisib) Work?

The molecule selectively inhibits PI3K alpha, the signalling enzyme that mutated PIK3CA keeps permanently switched on; paired with fulvestrant, which degrades the estrogen receptor, the combination attacks the tumor's two remaining growth supports at once. The clinical template is the SOLAR-1 trial of originator alpelisib: median progression-free survival of 11.1 months versus 5.7 months with fulvestrant alone, and 7.9 months added to median overall survival in PIK3CA-mutated patients. A generic does not re-run those trials — it must show bioequivalence to the reference product, which is the basis on which Lucius' alpelisib is sold.

Indications of LuciAlpe

In plain terms: PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer, combined with fulvestrant, after endocrine failure — the use that pays for the medicine — with the PROS severe-overgrowth use referenced under the international label that Lao registration follows. It is a generic alternative for patients who cannot access or afford Piqray, not a different therapy with different science.

Dosage and Administration

The standard dose is 300 mg once daily — two 150 mg tablets swallowed whole with food each morning. Do the packing arithmetic before ordering: one 28-tablet carton covers 14 days, so a treatment month is two cartons (56 tablets). Dose reductions to 250 mg and then 200 mg daily follow the same ladder as the originator label for manageable toxicity. Fulvestrant runs in parallel — 500 mg intramuscularly on days 1, 15 and 29, then once monthly. Missed doses can be taken with food within nine hours of the scheduled time; later than that, skip. After vomiting, never re-dose — resume the next day as normal.

Side Effects of LuciAlpe

Generic alpelisib carries the same effect profile as the original, and pretending otherwise would be dishonest: high blood sugar is the signature effect and needs baseline plus on-treatment glucose monitoring; diarrhea, mouth sores, rash, tiredness and reduced appetite are the commonly reported ones; creatinine and liver enzyme shifts appear on labs. The serious-risk list — severe hypersensitivity, severe skin reactions, pneumonitis, fetal harm — is identical, which is why the medicine stays behind prescription and monitoring no matter whose box it comes from. Report blistering rashes, breathlessness or persistent cough immediately; most other effects are managed with dose holds and standard supportive care.

Storage Instructions

Keep the carton at 20°C to 25°C (short excursions 15°C–30°C allowed), dry, out of direct light, blisters sealed until use — no refrigeration. Store away from children, and return expired tablets to a pharmacy for disposal rather than the household bin.

Why Choose LuciAlpe from GLT?

The reason patients and institutions choose a documented Lao generic is arithmetic: LuciAlpe typically costs a small fraction of the Novartis original for the same 150 mg strength and a bioequivalent product — which can be the difference between continuing therapy and stopping it. GLT adds the part generics buying actually hinges on: verification. We supply stock with the Lao FDA registration number printed on the carton (03 L 1076/24), batch documentation, pre-shipment photographs of the exact boxes we will send, and a direct human line on WhatsApp +86 15234153837 or [email protected]. If you would rather compare against the India-market original Pivikto or the EU Piqray, we will quote all of them side by side without pressure.

How to Order LuciAlpe (Alpelisib)

Send your required quantity to WhatsApp +86 15234153837 or [email protected]. GLT replies with a formal quotation, shipping options and payment details — usually within one working day — and dispatches sealed LuciAlpe cartons with export documentation on confirmation. Two-carton monthly schedules can be set up as recurring orders so the treatment calendar never breaks; institutions can request CoA and batch images before payment.

FAQ

Is a Lao generic as effective as Piqray? It must demonstrate bioequivalence to the reference product to be sold as alpelisib; clinically the molecule is the same and the effect profile is the same — what differs is price and the depth of the maker's trial portfolio.

How can I verify the registration? The carton carries Lao FDA registration number 03 L 1076/24 (test report 0386-24); we also provide batch documentation and photographs of the actual stock before dispatch.

How many boxes per month? Two — the 28-tablet carton is a 14-day supply at the standard two-tablets-per-morning dose.

Does LuciAlpe work for PROS? The Lao label references the international PROS use, but dosing for PROS differs completely from the breast cancer schedule and should only be set by the treating physician; for the PROS line we also list the Novartis brand Vijoice.

Can you supply other generics for comparison? Yes — we quote LuciAlpe against other verified alpelisib sources, original or generic, with landed-cost figures so the choice is yours on facts.